What Cefaclor AL Treats: Main Uses and Benefits

Cefaclor AL is a second-generation cephalosporin antibiotic applied across domains where additional symptomatic support is needed to manage and address a wide range of infections caused by susceptible strains of bacteria. This medicine is commonly used to help with symptoms linked to organ-specific functional stress across several areas of the body, making it relevant in clinical settings that involve acute or unstable symptom patterns.

It is used for managing conditions presenting with acute episodes, including respiratory tract infections (such as pneumonia and bronchitis), otitis media, urinary tract infections (like cystitis), and skin and soft-tissue infections. When applied in situations involving these infections, Cefaclor AL provides supportive relief that helps ease the overall symptom burden for patients. This supports general well-being during symptomatic phases.

“The medication is considered relevant in contexts involving heightened systemic burden caused by these types of infections.”

Quick Fact: Supports Patients During Episodes Where Symptoms Interfere with Routine Activities

This antibiotic is applied in addressing bacterial infections only. Appropriate use assists with maintaining functional stability during episodes of heightened discomfort.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Profile: Who Can and Cannot Use Cefaclor AL?

This section summarizes the population eligibility and exclusion criteria for Cefaclor, as documented in authoritative governmental regulatory sources.

Contraindicated Populations	Conditional/Restricted Use
Patients with known hypersensitivity or allergy to the cephalosporin group of antibiotics.	Patients with a history of penicillin allergy should be given the drug with caution due to the documented risk of cross-hypersensitivity.
Patients with a major allergy history to penicillin (due to cross-hypersensitivity risk).	Pregnant women: Use is recommended only if clearly needed, as safety in human pregnancy is not established.
Infants less than one month of age.	Nursing mothers: Caution should be exercised, as small amounts of the drug are detected in human milk.
Patients with hypersensitivity to any of the excipients in the formulation.	Patients with markedly impaired renal function require caution and careful clinical observation due to limited clinical experience.
	Individuals with a history of gastrointestinal disease, particularly colitis, should be prescribed the medicine with caution.

Age-Related Eligibility: Safety and effectiveness for use in infants less than one month of age have not been established, making this population ineligible. For adults, including the elderly, dosage adjustment for normal renal function is generally not necessary. Specific extended-release formulations may also have higher minimum age limits, such as 16 years.

The final eligibility status is determined by these official regulatory constraints, which dictate an absolute exclusion for individuals with hypersensitivity to cephalosporins or related drugs, and mandate caution for those with significant co-morbidities like renal impairment or a history of colitis.

Official Interactions with other medicines and products

The interaction profile for Cefaclor AL documents effects on renal excretion, coagulation status, and the absorption of the medicine itself.

Interacting Substance/Class	Official Interaction Outcome
Probenecid	Inhibits the renal tubular secretion of Cefaclor, which results in increased and prolonged serum concentrations of Cefaclor.
Oral Anticoagulants (e.g., Warfarin)	Co-administration has been associated with reports of a potential increase in prothrombin time.
Nephrotoxic Drugs (e.g., Aminoglycosides)	May increase the risk or severity of nephrotoxicity.
Bacteriostatic Antibacterials (e.g., Chloramphenicol)	Regulatory documents note the possibility of antagonism when co-administered.
Oral Contraceptives	Cefaclor may decrease the level or effect of the hormonal component by altering intestinal flora.

Timing and Administration Constraints

The total extent of Cefaclor absorption remains the same with or without food. However, taking Cefaclor with food results in the peak plasma concentration achieved being reduced by 50% to 75% and delayed, compared to taking the medicine in a fasting state. Antacids that contain aluminum or magnesium can diminish the absorption of Cefaclor extended-release tablets, necessitating a timing separation when they are administered.

Cefaclor AL is a beta-lactam antibiotic of the second-generation cephalosporin class. The molecule acts by interfering with the synthesis of the bacterial cell wall.

The active compound targets and binds to penicillin-binding proteins (PBPs), which are bacterial enzymes located on the inner surface of the bacterial cell membrane. Specifically, the compound functions as an inhibitor of transpeptidases (a type of PBP). This binding prevents the essential cross-linking of peptidoglycan chains, which are polymers that provide structural rigidity to the bacterial cell wall. The resulting defect in the cell wall integrity leads to increased osmotic pressure on the bacterial cell and subsequent cell lysis (rupture) and death. This mechanism affects the cell wall synthesis of gram-positive and gram-negative organisms.

How to Use Cefaclor AL: Administration Guidelines

Cefaclor AL is administered via the oral route. The medication is available as an immediate-release capsule, an oral suspension, and an extended-release (ER) tablet.

---

Labeled Dosing and Frequency

The standard adult dosing schedule for immediate-release forms is typically 250 mg every 8 hours, though this may be increased to 500 mg every 8 hours for managing more severe infections. The maximum daily dose is 4 grams. Dosing for the extended-release tablet is typically administered twice daily (every 12 hours).

Administration Conditions

Administration protocol is dependent on the specific formulation. Immediate-release capsules and the oral suspension can be taken with or without food. Conversely, the extended-release tablets must be ingested with a meal and must be swallowed whole, as they must not be crushed, split, or chewed. If using the suspension, the bottle requires shaking well before use.

Duration and Special Rules

Therapy typically lasts 7 to 10 days but is continued for at least 10 days when managing certain streptococcal infections. For specific populations, pediatric dosing (for children over 1 month) is determined by body weight, not exceeding 1 gram daily. If a dose is missed, standard practice is to skip the missed dose if the next scheduled dose is near, and a double dose is not taken.

Research Evidence / Overview of Studies for Cefaclor AL

Evidence for Use in Respiratory Tract Infections

Cefaclor was studied in the context of conditions associated with acute or disruptive episodes, such as pharyngitis, tonsillitis, and bacterial exacerbations of bronchitis. The primary evidence base consists of short-term Randomized Controlled Trials (RCTs). Researchers monitored two main axes: the clinical response and bacteriological outcomes (the measurement of pathogen presence at the site of infection). Comparative trials reported that the measured outcomes for both clinical and bacteriological responses were observed to be similar to those of other antibiotics evaluated.

Evidence for Use in Otitis Media

Cefaclor was evaluated in research contexts related to acute otitis media (AOM), primarily in children. The evidence base is supported by numerous RCTs and systematic reviews. Studies monitored clinical success and bacteriological eradication as the primary outcomes. Findings reported that measured clinical response rates met the trial's predefined success criteria in pediatric subjects evaluated for AOM. Research explored short-term changes, and findings reported that measurements of clinical response rates were observed to be similar to those of other antibiotics evaluated.

Evidence in Special Populations and Research Gaps

Research has explored Cefaclor in special populations, including children and individuals with reduced kidney function. Pharmacokinetic studies observed that the elimination of the drug was prolonged in subjects with reduced renal function. However, clinical data, including safety and dosing guidelines, have not been established for infants younger than one month. Small amounts of the drug is transferred into breast milk, but the effect on nursing infants is not fully known.

Long-term effects are not fully established. The evidence base focuses on short-term efficacy for acute episodes, meaning there is limited information available for long-term outcomes related to recurrence or prevention of subsequent disease. Findings indicate that the local measured activity of the medicine may be impacted by the ongoing evolution of bacterial resistance patterns.

Key Studies & References Cefaclor (Oral Route) - Drug information and uses (NIH/NLM MedlinePlus)

Common questions about Cefaclor AL (FAQ)

Q: Can Cefaclor AL cause problems with birth control pills?

A: Regulatory documents state that Cefaclor may potentially decrease the level or effect of the hormonal component in oral contraceptives. This is thought to occur by altering the normal bacteria in the digestive system. This possibility is noted in official documents when considering the risk of reduced effectiveness.

Q: What should I do if I feel dizzy while taking Cefaclor AL?

A: Official side effect profiles for Cefaclor list dizziness as a possible reaction. When individuals experience side effects such as dizziness, using caution during tasks like driving is a generally recommended step, and any concerning symptoms should be discussed with a healthcare provider.

Q: What are the most common reasons a doctor might prescribe Cefaclor AL?

A: Cefaclor is officially indicated for treating a variety of bacterial infections. These typically include infections of the respiratory tract (lungs and throat), the skin, the urinary tract, and the ear (otitis media). The decision to use this medicine is based on the healthcare provider's assessment of the type and nature of the bacterial infection.

Q: Do studies exist that confirm the official uses of Cefaclor AL?

A: Yes, official product information references clinical data and studies, including Randomized Controlled Trials, that have evaluated the clinical and bacteriological outcomes in relation to its approved uses. These studies focus on conditions such as respiratory tract infections and acute otitis media.

Q: What are the official warnings about taking Cefaclor AL with food?

A: Official administration conditions specify that the immediate-release form can be taken with or without food. However, taking it with food reduces and delays the peak concentration of the medicine in the blood. The extended-release form, conversely, is instructed to be taken with a meal.

Q: Can Cefaclor AL affect the results of a urine sugar test?

A: Official information indicates that Cefaclor is known to potentially cause false-positive results with certain urine sugar tests that use copper reduction methods. The medicine's use should be disclosed to healthcare providers before performing certain laboratory tests.

Q: Are there any specific dietary restrictions mentioned for people using Cefaclor AL?

A: Official drug labeling does not list general dietary restrictions. However, it is noted that antacids containing aluminum or magnesium can reduce the absorption of the extended-release form of Cefaclor, requiring a separation of administration timing.

Q: Why does Cefaclor AL sometimes cause changes in taste?

A: Changes in taste, or dysgeusia, are documented in official post-marketing reports for some patients using Cefaclor. While the precise reason is not fully detailed in patient information, it is a recognized side effect.

Q: Do official documents mention any mental or mood changes as a side effect of Cefaclor AL?

A: Yes, official adverse reaction lists have included nervous system effects. These can include symptoms such as hyperactivity, agitation, nervousness, insomnia, confusion, and, in very rare instances, hallucinations.

Q: Does Cefaclor AL impact laboratory tests other than blood clotting or urine sugar?

A: Official drug information states that Cefaclor can also potentially cause a false-positive direct Coombs test. This is a laboratory test used to screen for certain conditions that involve red blood cells, and a positive result may be associated with the presence of the drug.

How to Store and Dispose of Cefaclor AL?

Strict adherence to regulatory labeling ensures the stability and safety of Cefaclor AL. Storage requirements vary depending on the drug form:

• Dry Forms (Capsules/Tablets): Must be stored at controlled room temperature (e.g., 15 C to 30 C), protected from moisture and light, and kept in a tightly closed container.
• Reconstituted Suspension: Must be stored in a refrigerator (2 C to 8 C) and must not be frozen.

Stability and Child Safety

The liquid suspension has a time-bound stability, meaning it must be discarded after 14 days even if refrigerated. All forms of the medication must be stored out of the sight and reach of children and pets.

Disposal Requirements

Disposal of unused or expired Cefaclor AL must follow local official requirements. The product must not be thrown into wastewater (sinks or toilets); use a medication take-back program or authorized collection point where available.